More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB:NMLSF) is filing new provisional patent applications to the U.S. Patent and Trademark Office (USPTO) in order to protect potential conclusions from its psilocybin preclinical studies as well as its proprietary therapy with psilocybin and psilocybin-based tryptamine derivatives for neuroinflammatory disorders (NID).
这家加拿大生物科技公司Nova Mentis生命科学公司(OTCQB：NMLSF)正在向美国专利委员会提交新的临时专利申请美国专利商标局(USPTO)为了保护其裸盖菇素临床前研究的潜在结论，以及其使用裸盖菇素和基于裸盖菇素的色胺衍生物的专利治疗神经炎症性疾病(NID).
NOVA's therapeutic paradigm includes diagnosis, monitoring and treating neuroinflammatory diseases and conditions with psychoactive tryptamine derivatives. Their research program aims to respond to the need for an accurate and effective diagnosis & treatment of NID by generating clinical biomarker data for aberrant gene expression and cellular communication in neurological disease or injury, and by providing insights into possible interventions and disease monitoring.
Nova的治疗模式包括诊断、监测和治疗神经炎性疾病，以及使用具有精神活性的色胺衍生物治疗疾病。他们的研究计划旨在通过以下方式回应对NID准确有效诊断和治疗的需求神经系统疾病或损伤中异常基因表达和细胞通讯的临床生物标志物数据，并对可能的干预措施和疾病监测提供见解。
Dr. Marvin S. Hausman MD, chairman of NOVA's Scientific Advisory Board, affirmed that the current patent application filing represents a "major milestone" in their psilocybin research program.
马文·S·豪斯曼博士，Nova科学顾问委员会主席，肯定了目前的专利申请是他们裸盖菇素研究计划的一个重要里程碑。
"The company is now in a position to reveal the breakthrough preclinical psilocybin results uncovered in its treatment of fragile X syndrome (FXS)," Hausman said. "Oral repetitive doses of microdose psilocybin showed a more robust improvement in memory than the same doses given by injection. Metabolic changes of psilocybin within the small intestine and perhaps the microbiome may represent a new paradigm in the application of psilocybin to the treatment of autism spectrum disorder (ASD)."
豪斯曼说：“该公司现在能够公布在其治疗脆性X综合征(FXS)中发现的突破性临床前裸盖菇素结果。”“口服重复剂量的裸盖菇素比注射相同剂量的裸盖菇素能更有效地改善记忆。裸盖菇素在小肠和微生物体内的代谢变化可能代表了裸盖菇素在自闭症谱系障碍(ASD)治疗中的应用的新范例。”
As stated by the company, the psilocybin formulation was evaluated in two distinct rat models of autism in the laboratory of Dr. Viviana Trezza in Italy, and demonstrated psilocybin proof of efficacy and safety. In February, NOVA announced it had successfully completed its preclinical study which confirmed oral microdose psilocybin as a potential treatment option for ASD and FXS.
正如该公司所说，裸盖菇素制剂在两种不同的自闭症大鼠模型上进行了评估。Viviana Trezza博士在意大利，并证明了裸盖菇素的有效性和安全性。在2月份，Nova宣布已成功完成其临床前研究，证实口服微剂量裸盖菇素是一种潜在的ASD和FXS的治疗选择.
The February research found that a repeated low dose of the proprietary psilocybin drug NM-1001 significantly modulated behavioral and cognitive defects such as recognition memory in a genetic model of FXS. The conclusive data from the study will be presented at the 18th NFXF International Fragile X Conference later this year.
二月份的研究发现，反复服用低剂量的专有裸盖菇素药物NM-1001在FXS的遗传模型中，显著调节了行为和认知缺陷，如识别记忆。这项研究的决定性数据将在今年晚些时候举行的第18届NFXF国际脆性X大会上公布。
The fact is that NOVA keeps strengthening its intellectual property by presenting provisional patent applications to protect data from a number of trials recently.
事实是，Nova通过提交临时专利申请来保护数据免受最近几次审判的影响，从而不断加强其知识产权。
Previously, the company had filed provisional patent applications for the following: a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin, and a diagnostic/therapeutic combination of mRNA molecules that encodes proteins involved in the development of the neurodegenerative diseases FXS and ASD.
此前，该公司已经提交了以下临时专利申请：专有制造工艺用于生产裸盖菇素和色胺类似物，巴氏囊藻毒素和铜绿假单胞菌，以及信使核糖核酸分子的诊断/治疗组合它编码与神经退行性疾病FXS和ASD发展有关的蛋白质。
The conclusive data from NOVA's most recent study will be presented at the 18th NFXF International Fragile X Conference later this year.
NOVA最新研究的决定性数据将在今年晚些时候举行的第18届NFXF国际脆性X大会上公布。
Photo Courtesy of Pexels.
照片由Pexels提供。
译文内容由第三方软件翻译。